The Medical Letter on Drugs and Therapeutics
Enzalutamide (Xtandi) for Prostate Cancer (online only)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Revised 3/18/13: The last sentence in the Clinical Study section has been revised.

The FDA has approved enzalutamide (en za loo’ ta mide; Xtandi – Astellas/Medivation) for oral treatment of metastatic castration-resistant prostate cancer in patients previously treated with docetaxel (Taxotere, and generics). It is the second oral drug approved for this indication; abiraterone acetate (Zytiga), which is also approved for first-line use, was the first.1 Cabazitaxel (Jevtana), which is given parenterally, has a similar indication.2

MECHANISM OF ACTION — Enzalutamide acts on the androgen receptor-signaling pathway, a driver of metastatic castration-resistant prostate cancer, inhibiting nuclear translocation of the androgen receptor, DNA binding, and coactivator recruitment. In animal models it has been shown to induce tumor shrinkage. ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Enzalutamide (Xtandi) for Prostate Cancer (online only)
Article code: 1411c
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian